FILE PHOTO: Prescription bottle
Hide Caption

FDA: Roche drug works in early-stage breast cancer

a a a a
Share this story

WASHINGTON (AP) — The Food and Drug Administration has issued a positive review of a breast cancer drug from Roche that could soon become the first pharmaceutical option for treating the earliest stages of the disease.

In documents posted online, FDA scientists said women who received the drug Perjeta to treat early-stage breast cancer had significantly fewer tumors than women who received older drug combinations. While the results come from mid-stage trials of the drug, FDA scientists recommended accelerating approval of the drug.

That step is reserved for groundbreaking drugs to treat life-threatening diseases.

Perjeta was first approved last summer to treat women with aggressive breast cancer that has already spread to other parts of the body. But Roche's Genentech unit is now seeking approval to use the drug at a much earlier stage of the disease: after diagnosis and before surgery to remove the tumor.

Surgery to remove tumors is the first-line treatment for virtually all forms of cancer. If approved, Perjeta would be the first cancer drug approved for use as a pre-surgical step. Early-stage cancer drugs are still experimental, but doctors hope the approach could help shrink tumors to make them easier to remove, or eliminate the need for surgery altogether.

On Thursday, the FDA will ask an outside panel of cancer specialists whether Perjeta's benefits outweigh its risks for treating early-stage breast cancer. Among other questions, the experts will be asked whether the preliminary results reported by Genentech are likely to result in longer overall survival for patients. The government agency isn't required to follow the group's advice, though it often does.

The panel will review a 417-woman study comparing Perjeta in different combinations against older breast cancer treatments. When Perjeta was combined with Herceptin, another Genentech drug, and standard chemotherapy, 39 percent of women saw their cancer reach undetectable levels. Only 21 percent of women experienced the same results from taking Herceptin and chemotherapy .

Last year the FDA released guidelines for studying breast cancer drugs in the pre-surgical setting, with the aim of accelerating approval of promising therapies. Perjeta is the first drug to undergo FDA review since those recommendations were released. If approved, it could encourage more drugmakers to study cancer drugs for early-stage use.

"Despite advances in systemic therapy of breast cancer, there remains a need to expedite drug development and approval of highly effective therapies for patients with high-risk early-stage breast cancer," the FDA states in its review.

Like Herceptin, Perjeta only works in a subset of about 20 percent of breast cancer patients who carry a more aggressive form of the disease. These women have tumors that overproduce a protein known as HER-2 which makes cancer cells rapidly divide and grow.

Breast cancer is the second most deadly form of cancer in U.S. women, and is expected to kill more than 39,000 Americans this year, according to the National Cancer Institute.

FDA scientists stress in their review that Genentech's results are preliminary and will have to be confirmed in future trials. The company only measured the patients' immediate response to the drug, and did not submit follow-up data showing whether the cancer returned or whether women ultimately lived longer. But agency scientists said the company's approach "is reasonably likely to predict clinical benefit," and noted that Genentech is already enrolling patients in a late-stage trial that could confirm the results.

Since the early 1990s the FDA has granted accelerated approval to dozens of drugs based on promising early results, on the condition that their effectiveness is confirmed in later studies. That policy has been praised by patients with HIV, cancer and other deadly diseases where access to experimental treatments can mean life or death.

But the flipside of the program means removing drugs from the market if their initial promise isn't confirmed by later studies. In 2011 the FDA was criticized by some cancer patients when it revoked breast cancer approval for another Genentech drug, Avastin. The FDA concluded that the drug did not help breast cancer patients live longer or bring enough other benefit to outweigh its dangerous side effects. The drug is still approved to treat colon cancer and other forms of the disease.

The FDA is scheduled to make a decision on whether to approve Perjeta for early-stage breast cancer by Oct. 31.FDA: Roche drug works in early-stage breast cancer

Copyright 2013 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Print this article

Comments

Hmm... It looks like you’re not a WCPO Insider. or Subscribe now to contribute!

More Health News
Batter Up! Health, safety at a diamond near you
Batter Up! Health, safety at a diamond near you

In this week's "Ask the Nurse," spring means bats are swinging, balls are flying, and players of all ages are sliding into…

Salmonella decline seen in food poisoning report
Salmonella decline seen in food poisoning report

The government's latest report card on food poisoning shows a dip in salmonella cases but an increase in illnesses from bacteria in raw…

Study: Girls view sexual violence as normal
Study: Girls view sexual violence as normal

New research from the journal Gender & Society shows girls view sexual violence as a normal part of life.

Study: Diabetic heart attacks, strokes falling
Study: Diabetic heart attacks, strokes falling

In the midst of the diabetes epidemic, a glimmer of good news: Heart attacks, strokes and other complications from the disease are plummeting.

How safe is your favorite restaurant?
How safe is your favorite restaurant?

A WCPO analysis of 32,474 violations at 5,579 food-service facilities found ethnic restaurants have higher violation counts per inspection…

Prof: Want fewer preemies? Stop cycle of abuse
Prof: Want fewer preemies? Stop cycle of abuse

A local girl's  haunting story should serve as a wake-up call about the vulnerability poor young girls, in our city and in our…

Diabetics beware: Here come insurance companies
Diabetics beware: Here come insurance companies

Diabetics beware. Your insurance company is looking for you.

Can new face change look of health care system?
Can new face change look of health care system?

Abruptly on the spot as the new face of "Obamacare," Sylvia Mathews Burwell faces steep challenges, both logistical and political.

Dieters move past calories, food makers follow
Dieters move past calories, food makers follow

Obsessing over calories alone has left dieters with an empty feeling.

VIDEO: Race day can bring injuries to runners
VIDEO: Race day can bring injuries to runners

Thousands of runners are getting ready for the 16th annual Flying Pig Marathon . They’ve run countless miles and worked for months.…